BidaskClub cut shares of Illumina (NASDAQ:ILMN) from a buy rating to a hold rating in a research note released on Wednesday.
A number of other brokerages have also commented on ILMN. Citigroup lifted their price target on Illumina from $180.00 to $220.00 and gave the stock a neutral rating in a report on Wednesday, October 25th. Robert W. Baird upgraded Illumina from a neutral rating to an outperform rating and lifted their price target for the stock from $184.00 to $228.00 in a report on Wednesday, October 25th. Zacks Investment Research upgraded Illumina from a hold rating to a buy rating and set a $229.00 price target on the stock in a report on Friday, October 27th. Barclays boosted their target price on Illumina from $150.00 to $185.00 and gave the company an equal weight rating in a research note on Wednesday, October 25th. Finally, Argus boosted their target price on Illumina from $205.00 to $235.00 and gave the company a buy rating in a research note on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company. Illumina has an average rating of Buy and a consensus target price of $201.98.
Shares of Illumina (NASDAQ:ILMN) opened at $217.65 on Wednesday. The company has a market capitalization of $31,341.82, a price-to-earnings ratio of 62.77, a P/E/G ratio of 3.55 and a beta of 0.79. Illumina has a fifty-two week low of $121.47 and a fifty-two week high of $230.72. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. Illumina’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same period last year, the company posted $0.97 earnings per share. analysts anticipate that Illumina will post 3.75 EPS for the current fiscal year.
In related news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $211.11, for a total transaction of $4,222,200.00. Following the sale, the director now directly owns 539,176 shares in the company, valued at approximately $113,825,445.36. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $226.55, for a total value of $283,187.50. Following the sale, the director now owns 9,088 shares in the company, valued at $2,058,886.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 166,150 shares of company stock worth $34,767,331. 0.89% of the stock is currently owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the stock. Moors & Cabot Inc. raised its stake in shares of Illumina by 7.1% during the 3rd quarter. Moors & Cabot Inc. now owns 7,500 shares of the life sciences company’s stock valued at $1,497,000 after purchasing an additional 500 shares during the period. IFM Investors Pty Ltd bought a new stake in shares of Illumina during the 3rd quarter valued at $804,000. DF Dent & Co. Inc. raised its stake in shares of Illumina by 4.0% during the 3rd quarter. DF Dent & Co. Inc. now owns 486,530 shares of the life sciences company’s stock valued at $96,917,000 after purchasing an additional 18,741 shares during the period. Neuberger Berman Group LLC raised its stake in shares of Illumina by 10.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 5,384 shares of the life sciences company’s stock valued at $1,072,000 after purchasing an additional 491 shares during the period. Finally, Virtu Financial LLC purchased a new position in Illumina during the third quarter worth about $577,000. Institutional investors own 91.75% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/10/illumina-ilmn-lowered-to-hold-at-bidaskclub.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.